Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities (2010 - 2026)

Northwest Biotherapeutics' Preferred Stock Liabilities history runs 11 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• On a quarterly basis, Preferred Stock Liabilities fell 14.73% year-over-year to $12.5 million in Q1 2026; TTM through Mar 2026 was $12.5 million, a 14.73% decrease from a year earlier, with the FY2025 full-year figure at $12.7 million, down 18.04% from the prior year.
• Preferred Stock Liabilities fell to $12.5 million in Q1 2026 per NWBO's latest filing, from $12.7 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $27.7 million in Q3 2023 and bottomed at $12.5 million in Q1 2026.
• The 5-year median for Preferred Stock Liabilities is $15.9 million (2024), against an average of $18.0 million.
• Across the five-year window, Preferred Stock Liabilities soared 101.27% in 2023 and sank 42.61% in 2024, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $23.1 million in 2022, then slipped by 18.83% to $18.7 million in 2023, then fell by 17.15% to $15.5 million in 2024, then fell by 18.04% to $12.7 million in 2025, then fell by 1.78% to $12.5 million in 2026.
• Per Business Quant, the three latest NWBO Preferred Stock Liabilities figures stand at $12.5 million (Q1 2026), $12.7 million (Q4 2025), and $13.4 million (Q3 2025).